Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 47, 979-982, February 15, 1987]
© 1987 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parker, W. B.
Right arrow Articles by Klubes, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parker, W. B.
Right arrow Articles by Klubes, P.

Dissociation of 5-Fluorouracil-induced DNA Fragmentation from Either Its Incorporation into DNA or Its Cytotoxicity in Murine T-Lymphoma (S-49) Cells1

William B. Parker2, Katherine A. Kennedy and Philip Klubes3

Department of Pharmacology, The George Washington University Medical Center, Washington, DC 20037

We have shown previously (W. B. Parker and P. Klubes, Cancer Res., 45: 4249–4256, 1985) that uridine (10 µM) enhanced the cytotoxicity of 5-fluorouracil (FUra) in cultured mouse T-lymphoma (S-49) cells. Here we show, by the use of colony formation assays, that approximately 50% of the cytotoxicity of FUra plus uridine could be prevented by the simultaneous administration of thymidine (2.5 to 10 µM). In order to explain our observation of a thymidine-preventable component of the cytotoxicity of the FUra plus uridine combination, we examined the incorporation of FUra into DNA. The DNA from FUra-treated S-49 cells was purified by cesium chloride gradient centrifugation and degraded to nucleosides by DNase I and Crotalus atrox snake venom. 5-[3H]-Fluoro-2'-deoxyuridine was not detected by high-pressure liquid chromatography in the hydrolysate of DNA from S-49 cells treated with 1.0 µM [3H]FUra, 1.0 µM [3H]FUra plus 10 µM uridine, or 2.4 µM [3H]FUra. In contrast, 5-[3H]fluoro-2'-deoxyuridine was detected in the DNA of L1210 cells treated with cytotoxic concentrations of either [3H]FUra or 5-[3H]fluoro-2'-deoxyuridine. Thus incorporation of FUra into the DNA of S-49 cells treated with cytotoxic concentrations of FUra was shown to be minimal or insignificant. Using alkaline elution techniques, however, fragmentation of the DNA was detected in S-49 cells treated with 1.0 µM FUra, 1.0 µM FUra plus 10 µM uridine, or 2.4 µM FUra (115-, 107-, and 159-rad equivalent single strand breaks, respectively). Most of the DNA fragmentation caused by FUra could be prevented by the inclusion of 2.5 µM thymidine with FUra during the incubation. Similar amounts of DNA fragmentation occurred with 1.0 µM FUra in either the presence or absence of 10 µM uridine. Because 1.0 µM FUra plus 10 µM uridine was more cytotoxic than 1.0 µM FUra alone, these results indicated that the enhancement of FUra cytotoxicity by uridine was not related to increased fragmentation of DNA.

1 This investigation was supported by Grants CH-160 (P. K.) and CH-274 (K. A. K.) from the American Cancer Society and by Training Grant T-32-CA-09223 from the National Cancer Institute, Department of Health and Human Services.

2 In part, from a dissertation presented to the Department of Pharmacology, The Graduate School of Arts and Sciences, The George Washington University, in partial fulfillment of the requirements for the Ph.D. degree. Present address: Department of Pharmacology, 916 FLOB 231-H, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514.

3 To whom requests for reprints should be addressed, at the Department of Pharmacology, The George Washington University Medical Center, 2300 Eye Street, NW, Washington, DC 20037.

Received 11/ 7/85. Revised 4/23/86. Accepted 11/12/86.




This article has been cited by other articles:


Home page
Therapeutic Advances in GastroenterologyHome page
J. M. Carethers
Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 33 - 42.
[Abstract] [PDF]


Home page
Cancer Res.Home page
M. Meyers, M. W. Wagner, H.-S. Hwang, T. J. Kinsella, and D. A. Boothman
Role of the hMLH1 DNA Mismatch Repair Protein in Fluoropyrimidine-mediated Cell Death and Cell Cycle Responses
Cancer Res., July 1, 2001; 61(13): 5193 - 5201.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
C. Lau, M. L. Mole, M. F. Copeland, J. M. Rogers, R. J. Kavlock, D. L. Shuey, A. M. Cameron, D. H. Ellis, T. R. Logsdon, J. Merriman, et al.
Toward a Biologically Based Dose-Response Model for Developmental Toxicity of 5-Fluorouracil in the Rat: Acquisition of Experimental Data
Toxicol. Sci., January 1, 2001; 59(1): 37 - 48.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1987 by the American Association for Cancer Research.